Drug, bio-affecting and body treating compositions inventions 11/07

20070275894 - Modulators of the abc transporter family and methods for their use: An isolated factor derived from the bacterium Pseudomonas aeruginosa and confirmed by proteomics to be a protein that reduces expression of ABC transmembrane proteins and active fragments and mimetics thereof are provided. Also provided is a method for inhibiting expression of ABC transmembrane proteins in cells by administering to the... Agent: Licata & Tyrrell P.C.

20070275923 - Cationic peptides for sirna intracellular delivery: What is described is a composition for delivery of a RNA molecule to a cell, comprising: a double stranded RNA (dsRNA) molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L... Agent: Nastech Pharmaceutical Company Inc

20070275930 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070275871 - Epo mimetic peptides and fusion proteins: EPM peptides, including EPM peptide-fusion proteins with increased serum half-life or serum stability are disclosed. Compositions comprising the EPM peptides or fusion proteins and methods of treating or preventing disorders by administering a therapeutically or prophylactically effective amount of an EPM peptide or fusion protein to a patient in need... Agent: Pfizer Inc. Patent Department, Ms 8260-1611

20070275875 - Method for preventing colon cancer: Provided are novel colon cancer preventives, and digestible food/drink additives and health supplements which not only are effective in body weight control and constipation prevention/treatment, but also have the action of accelerating the intestinal absorption of minerals. Sericin or it's hydrolyzed product is used as a colon cancer preventive, food/drink... Agent: Dilworth & Barrese, LLP

20070275876 - Method to increase the bioavailability of cysteine: A method for increasing the bioavailability of cysteine within an animal by reducing extracellular cysteine disulfide molecules to produce extracellular cysteine molecules. A membrane permeable thiol molecule that forms a membrane permeable disulfide molecule after becoming oxidized participates in thiol-disulfide exchange reactions on both sides of the cellular membrane, crossing... Agent: David M. Ott

20070275873 - Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting: The present invention provides a fusion protein comprising a first amino acid sequence of at least one immunoglobulin-binding domain of Protein L and a second amino acid sequence of a peptide or protein that does not bind an immunoglobulin Fc region, as well as methods of making and using the... Agent: Myers Bigel Sibley & Sajovec

20070275872 - Peptides with anti-obesity activity and other related uses: Novel peptides and uses thereof, including polypeptides and related molecules with uses, for example, in weight loss and for the treatment of obesity and related conditions associated with, for example, increased mass of adipocytes.... Agent: Duane Morris LLP

20070275874 - Use of leptin in wound healing: As described herein, leptin treatment significantly increased wound contraction and epithelial regeneration while reducing granulation tissue and wound area, consistent with a healing augmentation effect. Specifically, in leptin-treated wounds, the inventor found increased expression of smooth muscle-actin (-SMA) and collagens I, III and IV. Taken together, the inventor's results indicate... Agent: Davis Wright Tremaine LLP

20070275877 - Methods for treating or ameliorating ghrelin-associated diseases and disorders: Methods for modulating the effective levels of ghrelin are disclosed. These methods include the use of amylin, amylin agonists and amylin antagonists to regulate the effective levels of ghrelin. Methods for the prevention, treatment, or amelioration of ghrelin-associated diseases or disorders utilizing the methods for modulating ghrelin are also disclosed.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20070275878 - No-modified hemoglobins and uses therefor: Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070275883 - 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections: The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug... Agent: King & Spalding LLP

20070275882 - Nature-identical erythropoietin: The present invention relates to Erythropoietin, (i.e. Haemopoietin, Haematopoietin, or erthropoietic stimulating factor) (EPO) having glycoform profiles or a glycoform close or identical to naturally occurring EPO (nEPO) as well as processes and means for the production thereof. The present invention also concerns usage of the EPO obtained according to... Agent: Ostrolenk Faber Gerb & Soffen

20070275881 - Oligosaccharide compositions and use thereof in the treatment of infection: Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described.... Agent: Fish & Richardson PC

20070275879 - Use of ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome: The present invention relates to use of Ulinastatin and its pharmaceutical composition for treating and/or preventing Severe Acute Respiratory Syndrome (SARS). Ulinastatin is effective for treating and/or preventing SARS, particularly Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Ulinastatin is generally used as the pharmaceutical composition, preferably in... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070275880 - Virally-safe factor viii with a low content of higher multimers: La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070275885 - Microcystins as agents for treatment of cancer: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.... Agent: Buchanan, Ingersoll & Rooney PC

20070275884 - Use of modified cyclosporins for the treatment of hcv disorders: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula (I, Ia or II) as defined herein, having useful properties in the prevention or treatment of Hepatitis C infections.... Agent: Novartis Corporate Intellectual Property

20070275886 - Phalloidin derivatives and methods for their synthesis: The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.... Agent: Bell & Associates

20070275890 - Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example... Agent: Knobbe Martens Olson & Bear LLP

20070275897 - Collagen mimics: Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n, where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix... Agent: Quarles & Brady LLP

20070275893 - Compositions for enhanced epithelial permeation of peptide yy for treating obesity: Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount... Agent: Nastech Pharmaceutical Company Inc

20070275895 - Follistatin-3: The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070275889 - Gene expression technique: The present invention provides a method for producing heterologous protein comprising: (a) providing a host cell comprising a 2 μm-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein; (b) culturing the host cell in a... Agent: Synnestvedt & Lechner, LLP

20070275887 - Method of inhibiting secretase activity: The present invention provides a method for inhibiting secretase activity. A method for promoting the sensitivity of a secretase inhibitor, a method for binding synoviolin to Herp (homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain member 1), or the like is employed to inhibit secretase activity.... Agent: Dickstein Shapiro LLP

20070275892 - Novel chemokine mimetics synthesis and their use: The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example, and can be selected from a group... Agent: Technology & Intellectual Property Strategies Group PC Dba Tips Group

20070275891 - Obg3 globular head and uses thereof: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070275888 - Preventive/remedy for cancer: The present invention provides a substance that inhibits the binding of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7 or SEQ ID NO: 10, its partial peptide... Agent: Edwards Angell Palmer & Dodge LLP

20070275896 - Use of polypeptides in treating tissue injury: Provided are methods and compositions for treating tissue injury.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070275898 - Protein crystal comprising the processivity clamp factor of dna polymerase and a ligand, and its uses: The present invention relates to a protein crystal comprising the processivity clamp factor of DNA polymerase and a peptide of about 3 to about 30 amino acids, in particular of about 16 amino acids, said peptide comprising all or part of the processivity clamp factor binding sequence of a processivity... Agent: Young & Thompson

20070275899 - Treatment of demyelinating autoimmune disease with modified ordered peptides: Compositions and methods are provided for the treatment of demyelinating autoimmune disease. Therapeutic doses are administered of a combination of therapeutic ordered peptides or one or more modified therapeutic ordered peptide(s) comprising amino acids representing a consensus sequence of a protein identified as a target of the autoimmune T and... Agent: Townsend And Townsend And Crew, LLP

20070275900 - Prodrugs cleavable by cd26: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein... Agent: Clark & Elbing LLP

20070275901 - Synthesis, modification and reduction of primary structure of hypotensive peptides present in scorpion venom for optimizing their use as a hypotensive medicament: The present invention relates to synthetic and recombinant peptide primary structures including an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 12, wherein the primary structure includes an +aa-Pro-Pro amino acid in which “+aa” is Lys, Arg, His or a modified amino acid having... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070275902 - Treatment of phosphatidylinositol phospholipid disorders: Disclosed is a method of treating cell proliferative disorders, such as cancer, with amounts of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to phosphoinositol phospholipids.... Agent: Choate, Hall & Stewart LLP

20070275904 - Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same: The present invention is directed to conjugated compounds comprising a folate, or an analog or derivative thereof, and an aziridinyl epothilone analog, as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof, useful in the treatment of cancer or other folate-receptor associated conditions.... Agent: Fitzpatrick Cella (bristol-myers)

20070275905 - Salts of trimebutine and n-desmethyl trimebutine: Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable... Agent: Bennett Jones C/o Ms Roseann Caldwell

20070275903 - Tripeptide prodrug compounds: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making... Agent: Lahive & Cockfield, LLP

20070275906 - Compounds and compositions as channel activating protease inhibitors: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2),... Agent: Genomics Institute Of The Novartis Research Foundation

20070275907 - Glucose transport inhibitors and methods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.... Agent: Townsend And Townsend And Crew, LLP

20070275908 - Methods and compositions for the enzymatic synthesis of gangliosides: Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.... Agent: Townsend And Townsend And Crew, LLP

20070275909 - Novel hypocholesterolemic compounds: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.... Agent: The Webb Law Firm, P.C.

20070275910 - Phosphoramidate derivatives: The present invention provides a phosphoramidate compound comprising the structure (I) Formula (I) wherein: X comprises a monosaccharide group comprising the structure (II) or (III), 8 Formula (II), (III) B and B are independently selected from the group consisting of —O—, —CH2— and a bond, preferably —O—; R1 is selected... Agent: Fish & Richardson PC

20070275911 - Targeted drug-formaldehyde conjugates and methods of making and using the same: The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly... Agent: Sheridan Ross PC

20070275913 - Compositions and their uses directed to hepcidin: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods... Agent: Knobbe, Martens, Olson & Bear, LLP

20070275912 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B... Agent: Merck And Co., Inc

20070275925 - Asthma diagnosis and therapy: The invention provides drug assays, methods of diagnosing, and methods and compositions for treating asthma and other lung disease based upon the identification and/or use of agents which modulate CST1, HDAC9 or PRR4 levels or activity.... Agent: Townsend And Townsend And Crew, LLP

20070275918 - Induction of cellular senescence by cdk4 disruption for tumor suppression and regression: The invention provides methods of inhibiting growth of tumor cells comprising contacting the cells with a Cdk4 inhibitor. The invention also provides methods of treating patients having, suspected of having, or at a high risk for developing, a cancer, comprising treatment with a Cdk4 inhibitor. The invention also relates to... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275920 - Method for chromatographic separation of a nucleic acid mixture: The invention relates to a method for chromatographic separation of a nucleic acid mixture, particularly to the separation and purification of plasmid DNA from other components of the nucleic acid mixture, particularly other nucleic acids. The inventive method is particularly characterized in that plasmid DNA can be separated without adding... Agent: Mcdermott Will & Emery LLP

20070275916 - Methods of identifying compounds which modulate granulocite-colony stimulating factor (g-csf) dependent processes by modulation of the levels of suppressor of cytokine signaling (socs): The present invention relates generally to compounds which modulate cytokine-dependent processes. More particularly, the compounds of the present invention modulate responses to a colony stimulating factor and even more particularly to granulocyte-colony stimulating factor (G-CSF) by modulating the levels of molecules which inhibit G-CSF such as but not limited to... Agent: Scully, Scott, Murphy & Presser, P.C.

20070275921 - Oligomeric compounds that facilitate risc loading: The present invention provides double stranded compositions wherein one of the strands is useful in, for example, influencing the preferential loading the opposite strand into the RISC (or cleavage) complex. In particular, the present invention provides oligomeric compounds that comprise chemical modifications in at least one of the strands to... Agent: Woodcock Washburn LLP

20070275919 - Rna amidates and thioamidates for rnai: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3′→P5′ phosphoramidate (NP) and ribo-N3′→P5′ thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates... Agent: Perkins Coie LLP

20070275917 - Rna capable of suppressing expression of klf5 gene: An RNA capable of suppressing the expression of KLF5 gene, which comprises a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a sequence complementary to the sequence, and which has been designed from the nucleotide sequence of Kruppel-like factor 5 (KLF5) cDNA. Specifically, a double-stranded RNA... Agent: Greenblum & Bernstein, P.L.C

20070275922 - Rnai-mediated inhibition of igf1r for treatment of ocular angiogenesis: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.... Agent: Winstead PC

20070275924 - Synthetic lipid rafts and methods of use: Compositions and methods for delivering cargo to cells are provided. One aspect provides a synthetic vesicle containing caveolin 1 or a fragment thereof in an amount effective to form lipid rafts in the vesicle. The synthetic vesicles can be used to deliver polynucleotides, proteins, therapeutic agents, or a combination thereof... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070275914 - Therapeutic compositions: Therapeutic sRNA agents and methods of making and using are enclosed.... Agent: Fish & Richardson PC

20070275915 - Tmprss2 regulatory sequences and uses thereof: The present invention generally relates to substances and methods useful for the treatment of neoplastic disease. More specifically, it relates to cancer selective promoters and their use in oncolytic adenoviral vectors. The oncolytic adenoviral vectors are useful in methods of gene therapy. The promoters and the oncolytic adenoviral vectors are... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070275926 - Treatment of disorders of the peripheral nervous system: Pleiotrophin is used to treat various conditions, disorders, and diseases which involve damage to the peripheral nervous system. Such conditions include traumatic nerve damage, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, spinobulbar muscular atrophy, spinal muscular atrophy, diabetic neuropathy, and uremic neuropathy. Pleiotrophin can be provided as a protein or as a... Agent: Banner & Witcoff, Ltd.

20070275927 - Cosmetic use of polysaccharide compounds containing non-polymer siloxane graft(s): The invention relates to the cosmetic use of polysaccharide compounds containing non-polymer siloxane graft(s) that may be obtained by reacting a polysaccharide and a siloxane compound corresponding to formula (I), especially for the cosmetic treatment of keratin materials. The invention also relates to compositions comprising the said polysaccharide compounds in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275928 - Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes: or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases... Agent: Novartis Corporate Intellectual Property

20070275929 - Composition and method for controlling the transmission of noroviruses: Antimicrobial compositions having a rapid effectiveness against noroviruses and against bacteria are disclosed. The antimicrobial compositions contain a disinfecting alcohol, an organic acid, and water, wherein the composition has a pH of about 5 or less and the nonvolatile components of the composition are capable of forming a barrier film... Agent: Marshall, Gerstein & Borun LLP (dial)

20070275931 - Bisphosphonate compounds and methods: The invention provides, inter alia, novel bisphosphonate compounds and methods of making and using. In embodiments, the invention provides compounds and methods in connection with research and therapeutic applications, e.g., for tumor cell growth inhibition, activation of gammadelta T cells, inhibition of farnesyldiphosphate (FPPS) and/or undecaprenyldiphosphate synthase enzymes, bone resorption... Agent: Greenlee Winner And Sullivan P C

20070275932 - Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders: Disclosed are aryl, heteroaromatic and bicyclic aryl nitrone compounds and pharmaceutical compositions containing such derivatives. The disclosed compositions are useful for preventing and/or treating pain, neurodegenerative, autoimmune and inflammatory diseases or conditions in mammals.... Agent: Jones Day

20070275933 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070275934 - Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments: The present invention relates to a method for treating or ameliorating pancreatic cancer in an animal by administering to the animal active vitamin D compounds by high dose pulse administration in combination with one or more chemotherapeutic agents or radiotherapeutic agents/treatments.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070275935 - Estratriene derivatives: Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also suppress inflammation. The compounds are a class of estratriene derivates, and includes various... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275936 - Formulations and treatment methods: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds... Agent: Hollis-eden Pharmaceuticals, Inc.

20070275939 - Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis: The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides (e.g. hypercholesterolemia,... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070275937 - Therapeutic treatment methods: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070275938 - Therapeutic treatment methods: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070275940 - Composition containing vitamin d and phytoestrogens: The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and/or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising... Agent: Jenner & Block, LLP

20070275941 - Salt sensitivity and prevention of hypertension with drospirenone: The present invention relates to the use of drospirenone for manufacture of a medicament for prevention of development of high blood pressure (>140/90 mm Hg) in a patient who is predisposed to develop high blood pressure. The present invention further refers to methods of prevention of development of high blood... Agent: Millen, White, Zelano & Branigan, P.C.

20070275942 - Compositions and uses of et 743 for treating cancer: Et 743 is used in the preparation of a medicament for the treatment of the human body for cancer.... Agent: King & Spalding

20070275943 - Method and composition for treatment or prophylaxis of amyloidosis disorders: A method of treatment or prophylaxis of amyloidosis disorders in a patient the method comprising topically applying to an area of skin of the patient a composition comprising: one or more zinc chelators; and one or more dermal penetration enhancers.... Agent: Foley And Lardner LLP Suite 500

20070275944 - Antioxidants and methods of their use: The invention relates to compounds and compositions to treat some neurodegenerative diseases. In some embodiments, the invention relates to an antioxidant comprising a selenium atom and nitroxide group. In further embodiments, the antioxidant comprises peroxidase and superoxide dismutase activity. In some embodiments, the antioxidants are effective in treating neurodegenerative diseases... Agent: Medlen & Carroll, LLP

20070275945 - Immobilized 1,2-benzisothiazolin-3-one: The present invention provides novel antimicrobial immobilized 1,2-benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are attached. The present invention is also directed to methods for preparing the BIT/ZnO complexes, to BIT/ZnO complexes prepared by the novel... Agent: Robert F. Tavares C/o Troy Corporation

20070275946 - Cytokine inhibitors: e

20070275947 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070275948 - 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinium maleate or tosylate as antipyschotics: The present invention relates to novel salts of 7-[4-(4-chlorobenzyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and a pharmaceutically acceptable solvate thereof, pharmaceutical formulations, processes for their preparation, and their use in medicine. The chemical entities are useful in therapy, in particular as antipsychotic agents.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070275949 - Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases: The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.... Agent: Fish & Richardson P.C.

20070275950 - 2-phenylpyridine derivative: The present invention relates to a novel 2-phenylpyridine derivative or a salt thereof, wherein the pyridine ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at... Agent: Sughrue-265550

20070275951 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A and R1 to R3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070275952 - Tie-2 modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070275953 - 2-pyridinone derivatives, having hiv inhibiting properties: The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in the treatment of Acquired Immune Deficiency Syndrome (AIDS). The present invention further relates to the synthesis of said compounds... Agent: Merchant & Gould PC

20070275954 - Novel fused heterocycles and uses thereof: This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.... Agent: Astrazeneca R&d Boston

20070275955 - Method of treating tumors: A method of treatment for preventing or reducing tumor growth in a patient includes administering to the patient an effective about of taurolidine, taurultam or a mixture thereof, so as to prevent or reduce the tumor growth in the patient.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070275956 - Novel heterocyclic compounds: Disclosed are novel compounds of formula (I, having hypolipidaemic and hypocholesterolemic properties, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.... Agent: Nixon & Vanderhye, PC

20070275957 - Use of n-desmethylclozapine to treat human neuropsychiatric disease: Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.... Agent: Knobbe Martens Olson & Bear LLP

20070275958 - Use of oxicam compounds: The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo-oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood-brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or... Agent: Fulbright & Jaworski L.L.P.

20070275959 - Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents: Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: Formula (I) wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275960 - Phenyl and pyridyl compounds for inflammation and immune-related uses: r

20070275961 - Triazolo ' 1, 5-a ! pyrimidines and their use in medicine: Compounds of formula (IA) or (AB) are kinase inhibitors, especially of CDK2, and/or PDK1 and/or CHK1: wherein Ring A is an optionally substituted aryl, heteroaryl, carbocyclic or heterocyclic radical, Alk represents an optionally substituted clivaient C1-C6 alkylene radical; n is 0 or 1; Q represents a radical of formula -(Alk1)p-(X),(Alk2)s-Z... Agent: Banner & Witcoff, Ltd.

20070275962 - Heterobicyclic compounds as pharmaceutically active agents: Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases,... Agent: Brooks Kushman P.C.

20070275964 - Cannabinoid receptor ligands and uses thereof: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.... Agent: Pharmacia Corporation Global Patent Department

20070275963 - Pyrazolo[1,5-a]pyrimidines: In its many embodiments, the present invention provides certain pyrazolo[1,5-a]pyrimidine compounds which can have utility as inhibitors of cyclin dependent kinases as well as methods of preparing such compounds. The compounds can have potential utility for the treatment, prevention, inhibition, or amelioration of one or more diseases associated with the... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070275965 - Cxcr4 modulators: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation,... Agent: Townsend And Townsend And Crew, LLP

20070275966 - Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators: e

20070275967 - Pyrazolinols:

20070275968 - Substituted biphenyl derivative: R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6... Agent: Morgan & Finnegan, L.L.P.

20070275969 - Nanoparticles for oral administration of pharmaceutical agents of low solubility: The present invention relates to pharmaceutical compositions for the oral administration of pharmaceutical agents having low water solubility. Those agents are solubilized with a polymer suitable for the formation of nanoparticles, especially from the EUDRAGIT L and S series which release the active agent in specific target regions of the... Agent: Novartis Corporate Intellectual Property

20070275970 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are... Agent: Knobbe Martens Olson & Bear LLP

20070275971 - Insecticidal compositions: s

20070275972 - Pyridopyrazines and the use thereof as kinase inhibitors: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.... Agent: Goodwin Procter L.l.p

20070275973 - Aryl fused azapolycyclic compounds: e

20070275975 - 3-quinuclidinyl amino-substituted biaryl derivatives: wherein A is N or N+—O−; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by... Agent: Robert Deberardine D-377/ap6a-1

20070275974 - Pharmaceutical composition of piperazine derivatives: The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275976 - N-phenylpyrazole derivatives as pesticides: The invention relates to bis-5-pyrazolyl derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070275977 - N-oxides of pyridylmethyl -piperazine and -piperidine derivatives: wherein the substituents have the meanings given in the description, and wherein the oxidized nitrogen atom can be the nitrogen atom in the pyridyl ring of R5, or the nitrogen atom in the piperidine ring (when Z is carbon) or either one of the nitrogen atoms in the piperazine ring... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275978 - Of at use of an antagonist compound of at least one receptor selected from a group comprising beta-adrenergic receptors, a at1, 5-ht5 and galanin receptor for preparing a pharmaceutical composition for treating rosacea: The invention relates to the use of an antagonist of at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor, for the preparation of a pharmaceutical composition for treating rosacea.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070275979 - Novel compounds: This invention relates to novel phenyl sulfone compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070275980 - Amide derivatives, process for preparation thereof and use thereof as insecticide: Q2 represents a phenyl group or heterocyclic group having one or more substituents, at least one of the substituent being any of a C1-C4 haloalkoxy group, a C2-C6 perfluoroalkyl group, a C1-C6 perfluoroalkylthio group, a C1-C6 perfluoroalkylsulfinyl group and a C1-C6 perfluoroalkylsulfonyl group, an insecticide comprising the compound as the... Agent: Amin, Turocy & Calvin, LLP

20070275981 - (hetero)cyclycarboxamides for controlling pathogenic fungi: The invention relates to the use of (hetero)cyclylcarboxamides of general formula (I) and to the agriculturally useful salts thereof for controlling plant pathogenic fungi, the variables in formula (I) having the following designations: A represents phenyl or an at least monosaturated five-membered or six-membered heterocycle with 1, 2 or 3... Agent: Birch Stewart Kolasch & Birch

20070275982 - Method: A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor.... Agent: Astrazeneca R&d Boston

20070275983 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070275984 - Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors: The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of... Agent: Gardner Groff Greenwald & Villanueva. PC

20070275985 - Triazolopyrimidines: e

20070275986 - Use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R′—NH or R—NH—R′—NH— group, where R=straight or... Agent: Harness, Dickey & Pierce, P.L.C

20070275987 - Novel pyridopyprimidinone derivatives which are hm74a agonists: wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070275988 - Transition state structure and inhibitors of thymidine phosphorylases: The transition state structure of thymidine phosphorylase is provided, along with thymidine phosphorylase inhibitors that resemble the charge and geometry of the thymidine phosphorylase transition state. Also provided are methods of inhibiting a thymidine phosphorylase, methods of treating cancer, and methods of inhibiting angiogenesis which utilize the thymidine phosphorylase transition... Agent: Amster, Rothstein & Ebenstein LLP

20070275989 - Therapeutic treatment: A combination comprising candesartan and rosuvastatin for the prevention or treatment of arteriosclerosis and for the prevention of cardiovascular events is described.... Agent: Morgan Lewis & Bockius LLP

20070275990 - Heterocyclic spiro compound: (wherein D and G are cyclic group which may have a substituent(s) or alkyl which may have a substituent(s), W and Y are a bond or a spacer of which main chain has an atom number of 1-4, ringA and ringB are heterocyclic ring which may have a substituent(s), containing... Agent: Sughrue Mion, PLLC

20070275991 - Drug delivery from embolic agents: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 μm, and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used... Agent: Sughrue Mion, PLLC

20070275992 - Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers: The present invention provides methods for synthesizing novel tetrahydroquinoline derivatives that are useful for cancer chemotherapy and anti-viral applications. The present invention provides compounds useful for cancer chemotherapy and methods for the preparation of these compounds. The present invention also includes cancer chemotherapy methods.... Agent: Watov & Kipes, P.C.

20070275993 - Combinations of an anti emetic agent and an enkephalinase inhibitor: The present invention concerns new combinations of an anti-emetic agent and an enkephalinase inhibitor, the uses of said combinations for treating diarrhea and/or gastroenteritis.... Agent: Stites & Harbison PLLC

20070275994 - Novel antinfective compounds: The present invention describes novel antiinfective compounds of formula (I), process for their preparation and pharmaceutical compositions containing them.... Agent: Nixon & Vanderhye, PC

20070275995 - Thiobenzimidazole derivatives: e

20070275996 - Use of statins for the treatment of metabolic syndrome: The present invention relates to the use of a pharmaceutical composition consisting of a statin (especially fluvastatin or pitavastatin) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for the preparation of a medicament for the prevention or treatment of metabolic syndrome (or syndrome X).... Agent: Novartis Corporate Intellectual Property

20070275998 - Deoxynojirimycin and d-arabinitol analogs and methods of using: R1 is a substituted or unsubstituted alkyl group; W1-4 are independently selected from hydrogen, substituted or unsubstituted alkyl groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl groups; X1-5 are independently selected from H, NO2, N3, and NH2;Y... Agent: Foley And Lardner LLP Suite 500

20070275997 - Perhexiline for treating chronic heart failure: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of... Agent: Hoffmann & Baron, LLP

20070275999 - Pharmaceutical compositions containing a hypoglycemic agent(s) for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia: The present invention provides a pharmaceutical composition containing a hypoglycemic agent(s) as an active ingredient for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia. The present invention further provides a pharmaceutical composition for preventing or delaying the progression from impaired glucose tolerance, borderline diabetes, insulin resistance... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070276000 - Chemical compounds: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070276001 - Biphenyl-pyrazolecarboxamide compounds: The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking... Agent: Edwards Angell Palmer & Dodge LLP

20070276002 - Compounds and compositions as channel activating protease inhibitors: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2),... Agent: Genomics Institute Of The Novartis Research Foundation

20070276003 - Biphenyl derivatives: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl... Agent: Theravance, Inc.

20070276004 - Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases: Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an emollient such as dimethicone, glycerol or isostearyl isostearate are provided, which are useful in particular in the treatment of dermatological or mucosal diseases such as dry skin or atopic or contact dermatitis.... Agent: Novartis Corporate Intellectual Property

20070276005 - Tri-substitued 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6 disubstituted pyran derivatives: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.... Agent: Brooks Kushman P.C.

20070276007 - Administration of pharmaceuticals: A new administration regimen giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is received by two or more consecutive administrations of a unit dose of a H+, K+-ATPase with 0.5-4 hours interval or by a pharmaceutical composition with extended release, which may be... Agent: White & Case LLP Patent Department

20070276006 - Method for the treatment of gastrointestinal disorders: The present invention relates to combined use of (a) a specific prostaglandin (PG) compound and (b) a H+,K+-ATPase inhibitor for the treatment of gastrointestinal disorders.... Agent: Sughrue Mion, PLLC

20070276008 - Pharmaceutical formulation comprising glycine as a stabilizer: The present invention provides pharmaceutical formulations suitable for intravenous injection comprising a lyophilized anti-ulcerative agent reconstituted in isotonic solutions suitable for intravenous administration, such as 5% dextrose or 0.9% sodium chloride. The solutions are brought to a pH of between about 9 and about 12, preferably between about pH 10... Agent: Lahive & Cockfield, LLP

20070276009 - Compositions and methods for viral inhibition: The present invention discloses methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including carbazole derivatives useful for viral inhibition.... Agent: Novartis Vaccines And Diagnostics Inc.

20070276010 - Aminopyrazole derivatives as gsk-3 inhibitors: The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and... Agent: Pfizer Inc.

20070276013 - Active substance combinations with insecticidal properties: The present invention relates to novel active substance combinations containing thiacloprid and at least one of the active substances (1) through (24) listed in the disclosure and having very good insecticidal characteristics.... Agent: Bayer Cropscience Lp

20070276011 - Plasminogen activator inhibitor-1 inhibitor: e

20070276012 - Process for preparing thiazolidinediones: This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base, and b) combining the solution or... Agent: Novartis Corporate Intellectual Property

20070276014 - High concentration topical insecticies containing pyrethroids: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth... Agent: Stroock & Stroock & Lavan LLP

20070276015 - Crystal modification of torasemide: The present invention relates to the characterization of a new crystal modification III of torasemide, to a process for the preparation thereof by the use of controlled acidifying of alkaline solutions of torasemide with inorganic or organic acids with or without addition of a crystal seed, to its use as... Agent: Buchanan, Ingersoll & Rooney PC

20070276016 - Benzo[1,2,5]thiadiazole compounds: Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20070276017 - Thiadiazoline derivative: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —COR5 (wherein R5 represents lower alkyl and the like) and the like, R3 represents lower alkyl and the like, R4 represents aryl and the like, A represents —(CH2)n— (wherein n represents an integer of 1 to... Agent: Greenblum & Bernstein, P.L.C

20070276018 - Aziridinyl-epothilone compounds: wherein K is —O—, —S—, or —NR7—; A is —(CR8R9)—(CH2)m-Z- wherein Z is —(CHR10)—, —C(═O)—, —C(═O)—C(═O)—, —OC(═O)—, —N(R11)C(═O)—, —SO2—, or —N(R11)SO2—; B1 is hydroxyl or cyano and R1 is hydrogen or B1 and R1 are taken together to form a double bond; R2, R3, and R5 are, independently, hydrogen, alkyl,... Agent: Fitzpatrick Cella (bristol-myers)

20070276019 - Haloalkyl containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Millen, White, Zelano And Branigan, P.C. C/o Berlex Biosciences

20070276020 - Dicationic compounds for activity against trichomonas vaginalis: Dicationic compounds for the treatment of T. vaginalis infections are described. The presently described compounds exhibit in vitro activity against metronidazole-sensitive and -resistant T. vaginalis isolates. Furthermore, the presently described compounds demonstrate IC50 concentrations that were not elevated in the metronidazole resistant isolate, suggesting that their activity is not affected... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070276021 - Method for treatment of neurodegenerative disorders: A method for treatment of multiple sclerosis and other neurodegenerative diseases, disorders or conditions. An alkyl ester of imidazole carboxylic acid, preferably methyl 4-imidazolecarboxylate, is administered in a therapeutic amount. It is hypothesized that the alkyl ester of imidazole carboxylic acid serves to restore and/or maintain the intracellular/extracellular osmolyte gradient... Agent: Todd N. Hathaway

20070276022 - Optically active carboxamides: m

20070276023 - Oil-based suspension concentrates: New, oil-based suspension concentrates composed of at least one room-temperature-solid compound of the formula (I′), at least one penetrant, at least one vegetable oil, at least one nonionic surfactant and/or at least one anionic surfactant, and optionally one or more additives from the groups of the emulsifiers, foam inhibitors, preservatives,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070276024 - Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists: The present invention describes a method for treating a disease or condition associated with the activity of a G protein coupled receptor (GPCR) comprising administering an inverse agonist for the GPCR, alone or in combination with an agonist for the GPCR, to an organism with a disease or condition associated... Agent: Catalyst Law Group, Apc

20070276025 - Indirubin-type compounds, compositions, and methods for their use: Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In... Agent: Jones Day

20070276026 - Hydroxybenzamide derivatives and their use as inhibitors of hsp90: m

20070276027 - Crystalline forms of [r-(r* ,r*)]-2-(4-fluorophenyl)-beta, -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid: Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid (atorvastatin free acid) designated Form A and Form B, characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia,... Agent: Warner-lambert Company

20070276028 - Pesticidal n-phenylpyrazole derivatives: The invention relates to 5-(substituted dithio- or dioxy-alkylamino)pyrazole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20070276029 - Glutamine-containing energy imparting amino acid composition or amino acid solution: [Problems] Amino acid composition with substantially no side effects which can not only efficiently supplement energy but also elevate the motor function. [Means for Solving Problems] Energy-imparting amino acid composition or amino acid solution containing glutamine comprising proline, alanine, valine, isoleucine, lysine and the glutamine. The energy-imparting amino acid composition... Agent: Young & Thompson

20070276030 - Pyranobenzothiophene derivatives to treat infection with hepatitis c virus: wherein substitutions fat R1, R2, R3-R12, and Y are set forth in the specification; pharmaceutical compositions comprising said compound, methods of treating or preventing a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of said compound or pharmaceutical compositions including said compound and... Agent: Fitzpatrick Cella (wyeth)

20070276031 - Process for purifying (-)- 9-trans-tetrahydrocannabinol: A process for separating (−)-Δ9-trans-tetrahydrocannabinol from a mixture of cannabinoids is disclosed. The process comprises at least one chromatographic step wherein a mobile phase passes trough a stationary phase. The stationary phase comprises a derivatised polysaccharide and the mobile phase comprises carbon dioxide.... Agent: Ratnerprestia

20070276032 - Use of 8-prenylnaringenin for hormone replacement therapy: The invention provides a production method for the phytoestrogen 8-Prenylnaringenin, the preparation produced by this method and the use of 8-Prenylnaringenin for the production of a medicament for the prevention and treatment of hormone-dependent osteoporosis and of peri- and postmenopausal symptoms in women.... Agent: Mayer & Williams

20070276033 - Topical formulation including stabilized water-soluble and oil-soluble compositions: A topical formulation includes a water-soluble ingredient and an oil-soluble ingredient and includes a combination of water, a rheology modifier, and a water miscible organic solvent to stabilize the composition.... Agent: Tod R Nissle

20070276034 - Compounds, compositions and methods for the treatment of synucleinopathies: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.... Agent: Proteotech, Inc.

20070276035 - Treatment of neurotic disorders: Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalized anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.... Agent: Darby & Darby P.C.

20070276036 - Non-glycosidic and non-peptidic select inhibitors, and the use thereof: is described, as well as methods for their production. These compounds represent a new class of non-toxic, in vivo anti-inflammatory effective inhibitors of selectins, and do not exhibit the disadvantages of the glycosidic inhibitor complexes, and are furthermore more potent in vitro, compared to the known drug bimosiamose. Furthermore, medicaments... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070276037 - Cytoprotective effects of ethyl pyruvate: The present invention provides methods for conferring cytoprotection and treating, suppressing or reducing the incidence of ischemia. The methods make use of an ester or amide of an alpha-ketoalkanoic acid, such as ethyl pyruvate, or compositions comprising the same.... Agent: Pearl Cohen Zedek Latzer, LLP

20070276038 - Esters with antimicrobial, bioresistant and fungal resistant properties: A bromine/nitro moiety linked into the backbone of an ester or other compound over a wide range of occurrence rates provides antimicrobial, bio-resistant and fungal resistant properties for metal working fluids (MWF)s and other coatings. The moiety can be have the bromo and nitro groups linked to the same or... Agent: Clifford Kraft

20070276039 - Pharmaceutical uses for alpha2delta ligands: b

20070276041 - Ppar activity regulators:

20070276040 - Peptidyl arginine deiminase type iv inhibitor: wherein R1, R2 and R3 each independently represent a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, provided that at least one of R1, R2 and R3 does not represent a hydrogen atom; R4 represents an amino group which has a substituent; and R5 represents a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070276042 - Preparation and utility of substituted carboxylic acid compounds: The present disclosure is directed to modulators of cyclooxygenase (COX) enzymes and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of non-specific pain, tension-type pain, headache, migraine, lower back pain, sciatica,... Agent: Wilson Sonsini Goodrich & Rosati

20070276043 - Tyrosine derivatives as ppar-gamma-modulators: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)S—N(R4)—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPARγ modulators and, therefore, are useful for the treatment... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070276044 - Peeling cosmetic method using a 8-hexadecene-1,16-dicarboxylic acid: The present invention relates to a cosmetic process for treating visible and/or tactile skin irregularities, comprising the steps consisting in: (a) topically applying to the skin a composition containing, in a physiologically acceptable medium, at least 10% by weight of 8-hexadecene-1,16-dicarboxylic acid, (b) leaving the composition in contact with the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070276045 - Anti-bacterial compounds: e

20070276046 - Alpha-aminoamide derivatives useful as anti-inflammatory agents: Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects.... Agent: Young & Thompson

20070276047 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070276048 - Unit dose formulations comprising an inhalable solution of albuterol: The present invention relates to unit dose formulations comprising an inhalable albuterol solution, wherein the inhalation albuterol solution is formulated with albuterol free base, a tonicity adjusting agent, a pH adjusting agent and water. Methods of preparing the unit dose formulation are also provided.... Agent: Wilson Sonsini Goodrich & Rosati

20070276049 - Regulation of cell membrane-mediated effects: The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated s effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious... Agent: Fish & Richardson P.C.

20070276050 - Methods for identifying ask1 inhibitors useful for preventing and/or treating cardiovascular diseases: This invention is directed to methods for identifying apoptosis signal-regulated kinase 1 (“ASK1”) inhibitors useful for preventing and/or treating cardiovascular disease. This invention also relates to methods for preventing and/or treating cardiovascular disease in an animal by administering to the animal an ASK1 inhibitor.... Agent: Harness, Dickey, & Pierce, P.l.c

20070270362 - Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders: Methods and compositions are provided for treating inflammatory-related diseases and related disorders in a mammalian subject. The method provides administering to the mammalian subject one or more modulators of cyclin dependent kinase 4 (Cdk4) activity in an amount effective to reduce or eliminate the inflammatory-related disease or disorder or prevent... Agent: Woodcock Washburn LLP

20070270373 - Substituted aryl piperidinylalkynyladenosines as a2ar agonists: t

20070270374 - 2'-c-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof: The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C.... Agent: Dorsey & Whitney LLP

20070270384 - Process and intermediate: The invention relates to a new process useful in the preparation of pharmaceutical compounds such as 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate (AZD1152) and intermediates used therein.... Agent: Astrazeneca R&d Boston

20070270329 - Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cdna thereof: Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for... Agent: Merchant & Gould PC

20070270332 - Methods and assays useful in the treatment of alcohol dependence or alcohol abuse: A method for the treatment of alcohol abuse using daidzin and compounds analogous to daidzin is disclosed. Also disclosed is a method for screening compounds having antidipsotropic activity.... Agent: Cv Therapeutics, Inc.

20070270331 - Modulators of gluconeogenesis: The present invention provides methods of affecting gluconeogenesis by altering the levels or activity of DUSP4 and/or EGR1. Pharmaceutical compositions comprising or encoding modulators of gluconeogenesis are also disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20070270330 - Preventing airway mucus production by administration of egf-r antagonists: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The ESGF-R antagonist... Agent: Bozicevic, Field & Francis LLP

20070270333 - Methods of treating acute blood loss: The present invention relates to novel methods of using blood substitutes to treat acute blood loss and novel pharmaceutical compositions comprising blood substitutes. Blood substitutes useful for the methods of the present invention can (1) induce expression of erythropoietin as tested in a cell culture under normoxic conditions, and/or (2)... Agent: Jones Day

20070270335 - Methods for alleviating deleterious effects of 3-deoxyglucosone: